On December 20, 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), reported that Phil Hagerman, CEO and chairman, and Atul Kavthekar, CFO, will present at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA (Press release, Diplomat Speciality Pharmacy, DEC 20, 2017, View Source [SID1234522736]).

(Press release, Diplomat Speciality Pharmacy, DEC 20, 2017, View Source [SID1234522736])

Mr. Hagerman and Mr. Kavthekar are scheduled to present at the conference on Wednesday, Jan. 10, 2018, at 1:30 p.m. PT. A live audio-only webcast of the presentation and related presentation materials will be available on the investor relations section of the Company’s website at diplomat.is. The archived webcast and presentation materials will also be available for approximately 90 days at the same URL.

On December 20, 2017 Vectura Group plc (LSE: VEC) ("Vectura", "the Company"), an industry-leading device and formulation business for inhaled airways products, reported that James Ward-Lilley, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, 10 January 2018, at 9:30am PST / 17:30pm GMT (Press release, Vectura, DEC 20, 2017, View Source;customerKey=VecturaIntranet&storyID=13758359 [SID1234522731]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and a copy of the slides will be available on the Company’s website: View Source A recording will be available following the presentation.

Vectura will issue a 2017 pre-close trading update on Thursday 4th January 2018.

– Ends –

Enquiries

Vectura Group plc

+44 (0)1249 667700

Elizabeth Knowles – Director Investor Relations and Analysis

David Ginivan – VP Corporate Communications

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / Chris Welsh / Jessica Hodgson

On December 20, 2017 Mylan N.V. (NASDAQ, TASE: MYL) reported that its CEO, Heather Bresch, will present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top, in Boston, Mass., on Thursday, Jan. 4, 2018, at 4 p.m. ET (Press release, Mylan, DEC 20, 2017, View Source [SID1234522730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a live webcast of the presentation via the investor relations section of Mylan’s website at investor.mylan.com. An archived version also will be available following the live presentation and can be accessed at the same location for a limited time.

On December 20, 2017 Mylan N.V. (NASDAQ, TASE: MYL) reported that its CEO, Heather Bresch, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif., on Tuesday, Jan. 9, 2018, at 3 p.m. PT (6 p.m. ET) (Press release, Mylan, DEC 20, 2017, View Source [SID1234522729]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a live webcast of the presentation via the investor relations section of Mylan’s website at investor.mylan.com. An archived version also will be available following the live presentation and can be accessed at the same location for a limited time.

On December 20, 2017 BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, reported that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will host institutional investor and partnering meetings, at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018 (Press release, BioTime, DEC 20, 2017, View Source;p=RssLanding&cat=news&id=2323507 [SID1234522723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One-on-one meetings with Mr. Mohanty and/or Mr. Skibsted may be arranged by registering through LifeSci Advisors, LLC, by making a request via e-mail at [email protected], or by contacting David Nakasone, Director of Investor Relations at BioTime, at 510-871-4188 or [email protected].